SPPI Spectrum Pharmaceuticals Inc.

Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II

HENDERSON, Nev.--(BUSINESS WIRE)--

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent model. The abstract titled “Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy” will be part of the Special Populations, Survivorship, Outcomes, and Supportive Care session at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held June 22-24, 2020. Full details of the poster are as follows:

Abstract Title: Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy

Authors: Yu-Yon Kim., et al.

Session: Special Populations, Survivorship, Outcomes, and Supportive Care

Date and Time: June 22, 2020, 9 a.m. - 6 p.m. EDT

Poster Number: 2044 / 22

Location: Access to the AACR Virtual Annual Meeting II will be free to everyone. While access will be free, attendees will be required to register to view the meeting. .

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit .

SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals’ logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2020 Spectrum Pharmaceuticals, Inc. All Rights Reserved

EN
16/06/2020

Underlying

SPPISpectrum Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spectrum Pharmaceuticals Inc.

 PRESS RELEASE
Free
SPPI Spectrum Pharma...

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectru...

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Special Meeting”) on July 27, 2023. Under the terms of the Merger Agreement, Assertio Holdings, Inc. (Nasdaq:...

July 20, 2023 1 EN
 PRESS RELEASE
Free
SPPI Spectrum Pharma...

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Pr...

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a min...

May 17, 2023 1 EN
 PRESS RELEASE
Free
SPPI Spectrum Pharma...

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results ...

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the quarter compared to 70 in Q4 2022, an increase of 145%. Permanent J-Code for ROLVEDON we...

May 9, 2023 1 EN
 PRESS RELEASE
Free
SPPI Spectrum Pharma...

Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 202...

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operations while continuing to invest in core business objectives, including the commercializati...

March 22, 2023 1 EN
 PRESS RELEASE
Free
SPPI Spectrum Pharma...

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 F...

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link () , and you will be provided with dial in details. To avoid delays, we encoura...

March 17, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch